pioglitazone has been researched along with Chromosome-Defective Micronuclei in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone (PTZ) is an oral antidiabetic agent whose anti-cancer properties have been described recently." | 1.43 | Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay. ( de Castro-Prado, MA; Franco, CC; Mathias, PC; Morais, JF; Pereira, TS; Sant'Anna, JR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oz Gul, O | 1 |
| Cinkilic, N | 1 |
| Gul, CB | 1 |
| Cander, S | 1 |
| Vatan, O | 1 |
| Ersoy, C | 1 |
| Yılmaz, D | 1 |
| Tuncel, E | 1 |
| Morais, JF | 1 |
| Sant'Anna, JR | 1 |
| Pereira, TS | 1 |
| Franco, CC | 1 |
| Mathias, PC | 1 |
| de Castro-Prado, MA | 1 |
2 other studies available for pioglitazone and Chromosome-Defective Micronuclei
| Article | Year |
|---|---|
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem | 2013 |
Genotoxic investigation of a thiazolidinedione PPARγ agonist using the in vitro micronucleus test and the in vivo homozygotization assay.
Topics: Aspergillus nidulans; Cells, Cultured; DNA; DNA Damage; Humans; Hypoglycemic Agents; Loss of Heteroz | 2016 |